Latest QurAlis News & Updates

See the latest news and media coverage for QurAlis. We track all announcements, press releases, and industry mentions in real time, all in one place.

QurAlis

Biotechnology company developing neurodegenerative disease therapies

quralis.com

Headquarters: Cambridge, United States
Founded year: 2016
Company type: Private company
Number of employees: 80–200

Last updated Today

Latest news about QurAlis

In short: QurAlis advanced its precision medicine pipeline for ALS and epilepsy, reporting positive clinical data and securing a major licensing deal with Eli Lilly.

Company announcements

May 12 QurAlis

QurAlis reports ALS progression slowing from QRL-201 trial

CEO Kasper Roet and VP Sandy Hinckley presented the data at Target ALS Annual Meeting, and QRL-101 is expanded to epilepsy.

May 6 QurAlis

QurAlis shares updated interim data from ANQUR trial

Data shows dramatic slowing of disease in sporadic ALS patients, presented by CEO Kasper Roet at Target ALS Annual Meeting.

April 30 QurAlis

QurAlis announces speakers at TargetALS Meeting

CEO Kasper Roet presents ANQUR trial data; VP Sandy Hinckley discusses QRL-101 for ALS and epilepsy.

March 25 QurAlis

QurAlis presents interim ANQUR trial data

CTO Hagen Cramer spoke at RNA Leaders Europe conference and co-hosted a workshop on RNA therapy delivery. QRL-201 aims to restore STMN2 expression in ALS patients.

Media coverage

February 26 ALS News Today

Experimental ALS therapy QRL-201 shows potential to slow disease decline

Experimental therapy QRL-201 shows potential to slow ALS progression by restoring a vital nerve protein. Interim Phase 1/2 data indicate that QRL-201 restores Stathmin-2 levels...

February 23 Morningstar

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS

QurAlis Demonstrates Effects on Disease Progression and Target Engagement in ANQUR Clinical Trial of QRL-201, a First-in-Class Precision Medicine in Development for Sporadic ALS First...

February 21 Endpoints News

QurAlis’ ALS drug sees early positive signal, but questions remain

QurAlis believes the biomarker data from the Phase 1/2 study are strong enough to move QRL-201 to a pivotal trial. But the experiment failed to...

1 December 2025 Clinical Trials Arena

QurAlis announces Phase I QRL-101 trial topline results in ALS

QurAlis has announced topline results from its Phase I proof-of-mechanism clinical trial of QRL-101 in patients with ALS.

Never miss news about QurAlis

Track QurAlis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

QurAlis competitors & trending companies

Browse news for competitors to QurAlis and other trending companies.